摘要
目的比较重组人血小板生成素与人血丙种球蛋白对难治性血小板减少性紫癜的治疗效果。方法选取2011年7月~2015年6月三明市第二医院血液科收治的70例难治性血小板减少性紫癜患者,按随机数字表法将其分成甲组和乙组,每组35例。甲组采用重组人血小板生成素进行治疗;乙组采用人血丙种球蛋白进行治疗。比较两组的治疗效果、不良反应发生率、血小板变化时间、住院时间及治疗前、后血小板计数和免疫功能。结果两组治疗效果及不良反应发生率比较,差异无统计学意义（P〉0.05）;乙组出血停止时间、血小板上升时间、血小板达正常时间及住院时间均明显短于甲组（P〈0.05）;两组治疗前血小板计数及免疫功能各指标水平均比较,差异无统计学意义（P〉0.05）;两组治疗后血小板计数比较,差异无统计学意义（P〉0.05）;治疗后,乙组免疫功能各指标水平均明显高于甲组（P〈0.05）。结论重组人血小板生成素和人血丙种球蛋白都是治疗难治性血小板减少性紫癜安全而有效的方式,且人血丙种球蛋白具有起效快、恢复时间短的优势,有助于患者免疫功能的改善。
Objective To compare the effectiveness of application of recombinant human thrombopoietin（TPO） and human gamma globulin（HGG） in the treatment of patients with refractory idiopathic thrombocytopenic purpura（ITP）.Methods 70 patients with refractory ITP who had been treated in department of hematology,the second hospital of Sanming city from July 2011 to June 2015 were randomly and evenly divided into group A and group B with 35 cases in each group.Group A were treated with rh TPO;Group B were treated with HGG.The therapeutic effect,adverse reaction rate,platelet change time,length of stay（LOS）,pre- and post- treatment platelet count and immune function of the two groups were compared.Results The therapeutic effect and adverse reaction rate of the two groups showed no significant difference（P〉0.05）;The bleeding stop time,platelet rise time,platelet back-to-normal time and LOS of group B was obviously shorter than that of group A respectively（P〈0.05）.The pre-treatment platelet count and immune function of the two groups showed no significant difference（P〉0.05）.The post-treatment platelet count of the two groups had no significant difference（P〉0.05）.The post-treatment immune function of group B was significantly higher than that of group A（P〈0.05）.Conclusion rh TPO and HGG are two safe and effective ways in the treatment of refractory ITP,but HGG demonstrates its advantages of rapid effectiveness and short recovery time,and contributes to the improvement of immune functions in patients with refractory ITP.
出处
《中国当代医药》
2016年第17期123-125,128,共4页
China Modern Medicine
